Loyal Valley Capital led a $100m series B financing round in Arctic Vision.

Venture capital firm Loyal Valley Capital led a $100m series B financing round in Arctic Vision, a China-based clinical-stage ophthalmology company. The round had participation from Tencent, Octagon Capital, and Dr. Adrian Cheng, renowned entrepreneur from New World Development Group, along with existing investors Nan Fung Life Sciences, Pivotal bioVenture Partners China and Morningside Ventures. "We are confident to leverage the proceeds from this financing round to further accelerate the clinical development of our pipeline assets and enhance commercialization capabilities, thus organically combining our in-house R&D efforts with external technologies to deliver safe and efficacious clinical solutions to patients. At the same time, we look forward to expanding our focus and attention to other countries in Asia, with the aim of addressing the unmet medical needs of even more patients across the region," Dr. Eddy Wu, Founder, Arctic Vision CEO and Board Director.